IPHA — Innate Pharma SA Income Statement
0.000.00%
Last trade - 00:00
- $178.18m
- $173.55m
- €51.90m
- 19
- 10
- 47
- 15
2019 December 31st | R2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 69 | 56.2 | 12.1 | 49.6 | 51.9 |
Cost of Revenue | |||||
Gross Profit | 65.8 | 52.6 | 9.05 | 46 | 49 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 96 | 55.1 | 59.9 | 107 | 64.6 |
Operating Profit | -27.1 | 1.08 | -47.8 | -57.4 | -12.7 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -20.8 | -0.829 | -45.5 | -58 | -7.57 |
Provision for Income Taxes | |||||
Net Income After Taxes | -20.8 | -0.829 | -45.5 | -58 | -7.57 |
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | -20.8 | -64 | -52.8 | -58.1 | -7.57 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -20.8 | -64 | -52.8 | -58.1 | -7.57 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.31 | -0.011 | -0.572 | -0.213 | -0.094 |
Dividends per Share |